Using botulinum toxin to treat involuntary movement disorders
Official title: Botulinum Toxin for the Treatment of Neurological Disorders
Run by National Institutes of Health Clinical Center (CC) · NCT00001208 · Data updated 2026-11-12
This study tests whether botulinum toxin can help people with involuntary movement disorders by customizing the treatment for each patient and using special techniques to give the injections.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 2 Years to 100 Years |
| Sex | All |
| Enrollment | 2000 (estimated) |
| Sponsor | National Institutes of Health Clinical Center (CC) NIH |
| Locations | 1 site (Bethesda, Maryland) |
| Status | Recruiting |
| Started | October 26, 1989 |
| Registry record updated | November 9, 2026 |
| Trial ID | NCT00001208 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals aged 2 years and older with movement disorders such as dystonia, hemifacial spasm, and spasticity that may respond to BTX treatment.
✕Probably not a fit
Patients who are pregnant, breastfeeding, or require certain antibiotics may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the efficacy of botulinum toxin (BTX) for treating various movement disorders characterized by involuntary muscle spasms. It focuses on tailoring BTX treatment to individual patients and employing specific injection techniques, including EMG and ultrasound guidance. The protocol allows for the observation of patients receiving standard BTX injections, contributing to a better understanding of the natural history of their conditions and their responses to treatment. Additionally, it serves as a training platform for physicians in the administration of BTX.
Why it matters
Potential benefit: If successful, this approach could significantly improve the management of movement disorders and enhance the quality of life for affected patients.
How similar studies have gone: Previous studies have demonstrated the efficacy of botulinum toxin for various movement disorders, indicating a promising approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
* INCLUSION CRITERIA: 1. Patients 2 years and older, will be eligible for participation if they have a disorder that, in the judgment of the treating physician, might be amenable to treatment with BTX. 2. Applicable disorders include but are not limited to dystonia, hemifacial spasm, blepharospasm, tremor, tics, vocal fold tremor, oral lingual dyskinesia, tardive dyskinesia, spasticity, and spasmodic dysphonia. EXCLUSION CRITERIA: 1. Women who are planning on becoming pregnant, are pregnant or breastfeeding, for the duration of the condition. 2. Subjects who require treatment with an aminoglycoside antibiotic, until treatment is complete. 3. For laryngeal injections, subjects must have a paradoxical vocal fold movement with intermittent stridor due to either gastroesophageal reflux or emotional disorders.
Where it's running
-
National Institutes of Health Clinical Center
Bethesda, Maryland, United States Recruiting
Study contacts
- Principal investigator: Debra J Ehrlich, M.D. — National Institute of Neurological Disorders and Stroke (NINDS)
- Study coordinator: Vivian S Koo
- Email: vivian.koo@nih.gov
- Phone: (301) 435-8518
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Developing algorithms to restore complex movement after paralysis using non-invasive sensors in healthy volunteers
This project tests whether signals from non-invasive sensors worn by healthy volunteers can train algorithms to control computers or assistive devices that might help people with paralysis.
-
Long-read genome sequencing to help diagnose dystonia
Researchers test long-read genome sequencing to see if it can provide a genetic diagnosis for people with dystonia and related movement disorders when standard tests have not.
-
Registry and natural history of epilepsy-dyskinesia syndromes
This registry will collect health data and biological samples from people of all ages who have a genetic diagnosis of epilepsy-dyskinesia syndromes to see how their genes relate to their movement and seizure symptoms over time.
-
Registry and biobank for neuroimmunological diseases
This study is trying to see if certain antibodies in the brain are linked to neurological disorders like encephalopathy and psychosis, and how they might affect patients' health.
-
Brain activity in movement disorders: basal ganglia, thalamus, and cerebellum
We will record brain electrical signals from adults with movement disorders, both with and without deep brain stimulators, to see if specific signal patterns match their symptoms.
-
Mindfulness program for people with Parkinson's and their caregivers
This study tests whether a mindfulness program can help people with Parkinson's and their caregivers feel better emotionally and improve their relationship.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.